Biocon Appoints Shreehas Tambe as CEO & Managing Director, Effective April 1, 2026

Biocon Limited has announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, effective April 1, 2026. This appointment follows approvals from the Nomination & Remuneration Committee and the Board of Directors. Tambe will lead the combined platform of biosimilars and generics, strengthening the Company’s ability to operate at scale and compete effectively in global markets. The integration of Biocon Biologics Limited as a wholly owned subsidiary of Biocon Limited has created a simplified and unified corporate structure. Biocon is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies. Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, said: “Biocon has consistently grown by anticipating patient needs and building ahead of the curve...”